ArticleMalaria journal2019
Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages.
Article in Malaria journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 84 citations in OpenAlex.
- Overcoming immunogenic gaps in malaria subunit vaccines by broadening CSP regions targeted.The Journal of experimental medicine · 2026Article
- Anti-malaria antibody engineering broadens recognition motifs and reveals new homotypic interactions that enhance protective breadth.Nature communications · 2026Article
- Relevance of the antibody Fc fragment and epitope valency in protection against malaria sporozoites.EMBO reports · 2026Article
- Mannosylated nanoparticle immunogens enhance the circumsporozoite protein-specific B cell response and improve protection against sporozoite challenge.bioRxiv : the preprint server for biology · 2026Article
- Robust Bioconjugated Antigens Induce Immune Responses Preventing Malaria Infection and its Transmission.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Deep learning-enabled scaffolding of spatial arrays of PfCSP epitopes.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- mRNA delivery of circumsporozoite protein epitope-based malaria vaccines induces protection in a mouse model.NPJ vaccines · 2025Article
- Immunization with VLP-based vaccines induces high IgG antibody titers in dermal interstitial fluid.NPJ vaccines · 2025Article
- Comparison of major, minor and junctional circumsporozoite protein epitopes for malaria vaccine design.NPJ vaccines · 2025Article
- Anti-Malaria Antibody Engineering Broadens Recognition Motifs and Reveals New Homotypic Interactions that Enhance Protective Breadth.bioRxiv : the preprint server for biology · 2025Article
- Cethromycin pharmacokinetics and pharmacodynamics for single dose cure ofAntimicrobial agents and chemotherapy · 2025Article
- Virus-like particle vaccines targeting a key epitope in circumsporozoite protein provide sterilizing immunity against malaria.NPJ vaccines · 2025Article
- Article
- Epitope specificity of antibody-mediated protection induced in mice by the malaria vaccine RTS,S/AS01.NPJ vaccines · 2025Article
- Elicitation of liver-stage immunity by nanoparticle immunogens displaying P. falciparum CSP-derived antigens.NPJ vaccines · 2025Article
- FcγR binding differentially contributes to protection by two human monoclonal antibodies targetingScience translational medicine · 2025Article
- Targeting Bottlenecks in Malaria Transmission: Antibody-Epitope Descriptions Guide the Design of Next-Generation Biomedical Interventions.Immunological reviews · 2025Review
- Virus-like particle-based vaccines targeting themSphere · 2025Article
- iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA.NPJ vaccines · 2025Article
- Protective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein.Science (New York, N.Y.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe circumsporozoite protein (CSP) of Plasmodium is a key surface antigen that induces antibodies and T-cells, conferring immune protection in animal models and humans. However, much of the work on CSP and immunity has been developed based on studies using rodent or non-human primate CSP antigens, which may not be entirely translatable to CSP expressed by human malaria parasites, especially considering the host specificity of the different species.
methodsUsing a genetically engineered strain of Plasmodium berghei that expresses luciferase, GFP and the Plasmodium falciparum orthologue of CSP, the effect of laboratory preparation, mosquito treatment and mouse factors on sporozoite infectivity was assessed using an in vivo bioluminescence assay on mice. This assay was compared with a PCR-based protection assay using an already described monoclonal antibody that can provide sterile protection against sporozoite challenge.
resultsBioluminescence assay demonstrated similar detection levels of the quantity and kinetics of liver-stage infection, compared to PCR-based detection. This assay was used to evaluate treatment of sporozoite and delivery method on mouse infectivity, as well as the effects of age, sex and strain of mice. Finally, this assay was used to test the protective capacity of monoclonal antibody AB317; results strongly recapitulate the findings of previous work on this antibody.
conclusionsThe PbGFP-Luc line and in vivo bioluminescence imaging provide highly sensitive read-outs of liver-stage infection in mice, and this method can be useful to reliably evaluate potency of pre-erythrocytic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.